低分子肝素、通心络胶囊联合应用治疗不稳定型心绞痛的疗效观察

Clinical observation of Tongxinluo capsule combined with low-molecular-weight haparin calcium in treating unstable angina pectoris

目的:观察低分子肝素、通心络胶囊联合应用治疗不稳定型心绞痛(UAP)的疗效。方法:将38例不稳定型心绞痛患者随机分成两组,治疗组(22例)用低分子肝素钙0.4ml,脐周交替注射1次/12h,共用7d;通心络胶囊4粒,3次/d,连用7d。对照组(16例)仅给常规抗心绞痛药物治疗,共7d。分别观察两组治疗前后心绞痛发作次数、心电图及血液流变学的变化。结果:治疗组UAP疗效、心电图及血液流变学的变化均比治疗前有显著改善,两组治疗后比较,治疗组全血粘度、纤维蛋白原、血细胞比容比对照组有显著改善(分别为P<0.01、<0.01、<0.05)。治疗组UAP疗效总有效率为95.5%,心电图疗效总有效率为90.9%;对照组UAP疗效总有效率及心电图疗效总有效率分别为68.7%及62.5%,两组比较差异非常显著(P<0.01)。结论:低分子肝素、通心络胶囊联合应用治疗不稳定型心绞痛,疗效确切,安全可靠。

Objective：To investigate the therapeutic effect of Tongxinluo capsule combined with low-molecular-weight haparin calcium on unstable angina pectoris. Methods：38 patients with unstable angina pectoris were randomly divided into two groups. 22 patients in treatment group were treated by 0. 4ml low-molecular-weight haparin calcium, once per 12 hours, for a treatment course of 7 days, and Tongxinluo capsule four pills once, three times a day, for a treatment course of 7 days. 16 patients in control group only were given antiunstable angina pectoris routine medicines for 7 days. The hemorhedogy changes and clinical effect and ECG changes were observed before and after treatment. Results ：The hemorhedogy changes including whole blood viscosity, hematocrit, fibriogen and ECG and clinical effect were improved after treatment, and the changes of whole blood viscosity, fibriogen, hematocrit in treatment group were superior to those of control group （ P〈0.01, P〈0.01, P〈0.05 ）. The clinical effect and ECG of the total effective rate in treatment group were 95.5% and 90.5%, respectively, and 68.7% and 62.5% in control group, respectively. There was a significant difference between two groups （P〈0.01）. Conclusion ：Tongxinluo capsule combined with low-molecular-weight haparin calcium is effective and safe in treating unstable angina pectoris.